ACE2 and COVID-19: The binding of SARS-CoV-2 may decrease ACE2 concentrations and increase the angiotensin II to angiotensin (1–7) ratio which may exacerbate pulmonary injury and tissue fibrosis.26 Angiotensin (1–7) may provide resilience from the development of pulmonary failure in COVID-19 further supporting this finding.49